All questions
Safety: Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration
5 questions · 1 source
Safety questions that apply to every indication of Vabysmo are on Vabysmo (faricimab-svoa), all indications: Safety.
Side effects
What side effects did Vabysmo cause in wet AMD trials?
Note: Table 1 columns are VABYSMO in AMD (N=664), DME (N=1,262), and RVO (N=641), then aflibercept in AMD (N=662), DME (N=625), and RVO (N=635), in that order; the AMD columns are the wet AMD trials (TENAYA and LUCERNE).
How common are cataracts with Vabysmo in wet AMD trials?
Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.
Can Vabysmo cause retinal pigment epithelial tears in wet AMD?
Note: In this row of Table 1, the first value is VABYSMO in AMD (N=664) and the second is aflibercept in AMD (N=662).
How common is eye inflammation with Vabysmo in wet AMD trials?
Note: In the Table 1 row, the first value is VABYSMO in AMD (N=664) and the fourth is aflibercept in AMD (N=662); the other values are from the DME and RVO trials.
Warnings
Does Vabysmo raise stroke or heart attack risk in wet AMD?